FibroGen
Gerardo Pangilinan, MS, DABT, is an accomplished toxicologist with extensive experience in nonclinical safety studies and regulatory submissions. Currently serving as Principal Scientist at FibroGen, Inc. since May 2020, Gerardo has previously held roles such as Toxicology Consultant and Research Associates Supervisor at various companies, contributing expertise in data analysis, study design, and compliance with regulatory guidelines. Gerardo's background includes significant positions at Pain Therapeutics, Amgen, and Roche, where Gerardo managed toxicology programs, supervised research teams, and played a key role in submitting various drug applications. Gerardo holds a Master's degree in Animal Science from the Agricultural University of Norway and a Bachelor's degree in Animal Science from the University of the Philippines.
This person is not in any teams
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.